Clinical trials: Refractory or Relapsed Multiple Myeloma
Relapsed and/or Refractory Multiple Myeloma
A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics (PK) of ixazomib alone or in combination with lenalidomide and dexamethasone (Rd), and antitumor activity of ixazomib in participants with RRMM.
- Trial name
- NCT04272775
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Volunteers
- 14 people
- Sponsor
- Takeda
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase I/II trial studies the side effects and best dose of leflunomide in treating patients with multiple myeloma that has come back (relapsed) or has not responded to previous treatment (refractory).
- Trial name
- NCT02509052
- Testing
- Laboratory Biomarker Analysis, Leflunomide, Pharmacological Study
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well ixazomib citrate, pomalidomide, dexamethasone, and stem cell transplantation works in treating patients with multiple myeloma that has come back or does not respond to treatment.
- Trial name
- NCT03202628
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Dexamethasone, Ixazomib Citrate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
The purpose of this study is to evaluate the effectiveness and side effects of the bortezomib, lenalidomide and dexamethasone combination in relapsed or relapsed and refractory multiple myeloma.
- Trial name
- NCT00378209
- Testing
- Bortezomib, Lenalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Dana-Farber Cancer Institute
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00726830
- Testing
- methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Trial of Romidepsin and Bortezomib for Multiple Myeloma
This is a phase II, open-label, multicenter, dual-strata study designed to evaluate the efficacy and safety of IV romidepsin given in combination with IV bortezomib for multiple myeloma (MM) patients with refractory or relapsed…
- Trial name
- NCT00765102
- Testing
- Bortezomib, Romidepsin
- Where
- 12 sites in United States
- Volunteers
- 32 people
- Sponsor
- Celgene
Multiple Myeloma
Study of Natalizumab in Relapsed/Refractory Multiple Myeloma
The primary objectives of the study are to evaluate the safety profile and the anti-tumor activity of 2 dose levels of natalizumab in participants with relapsed or refractory multiple myeloma.
- Trial name
- NCT00675428
- Testing
- BG00002 (natalizumab)
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Biogen
Multiple Myeloma and Plasma Cell Neoplasm
Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells.
- Trial name
- NCT00445484
- Testing
- pneumococcal polyvalent vaccine, lenalidomide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma
Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma
Study Objectives 1. To evaluate the efficacy of the combination of dexamethasone (Decadron®), thalidomide (Thalomid®), and lenalidomide (Revlimid®) as therapy for patients with relapsed or refractory multiple myeloma (MM) who…
- Trial name
- DexTR (NCT00538824)
- Testing
- dexamethasone, thalidomide, lenalidomide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Weill Medical College of Cornell University
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide
This randomized phase II trial studies how well pomalidomide and dexamethasone work compared to lenalidomide and dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement (relapsed)…
- Trial name
- NCT01794039
- Testing
- Dexamethasone, Lenalidomide, Pomalidomide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant
This phase II trial studies how well lenalidomide works in treating patients with progressive or recurrent multiple myeloma after a donor stem cell transplant.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00619684
- Testing
- lenalidomide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Fred Hutchinson Cancer Center
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of panobinostat and everolimus when given together and to see how well they work in treating patients with multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00918333
- Testing
- panobinostat, everolimus, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Mayo Clinic
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
The purpose of this study is to determine the safety and activity of the investigational drug known as carfilzomib in the treatment of multiple myeloma (MM) when it is given at doses above the usual dose after the standard dosing…
- Trial name
- NCT01775553
- Testing
- Carfilzomib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ajai Chari
Multiple Myeloma
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the effects of administration of daratumumab when combined with VELCADE (bortezomib) and dexamethasone compared with bortezomib and dexamethasone alone, for participants with relapsed or…
- Trial name
- NCT02136134
- Testing
- Daratumumab, VELCADE (Bortezomib), Dexamethasone
- Where
- 105 sites in United States, Australia and 13 more
- Volunteers
- 498 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)
The primary purpose of this clinical study is to determine the recommended clinical doses of vorinostat (MK-0683) and bortezomib administered in combination to participants with relapsed and/or refractory multiple myeloma (MM).
- Trial name
- NCT00858234
- Testing
- Vorinostat, Bortezomib
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma and Plasma Cell Neoplasm
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00687674
- Testing
- dexamethasone, sorafenib tosylate, Lenalidomide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
Note: The study data was transferred to zr pharma\& following the divestment of panobinostat to pharma\&. Prior to study completion under the sponsorship of Secura Bio, the study was initiated and conducted in part under the…
- Trial name
- PANORAMA_3 (NCT02654990)
- Testing
- Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets
- Where
- 80 sites in United States, Australia and 20 more
- Volunteers
- 248 people
- Sponsor
- pharmaand GmbH
Multiple Myeloma
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple…
- Trial name
- NCT00179647
- Testing
- lenalidomide, dexamethasone
- Where
- 69 sites in United States, Canada
- Volunteers
- 1,913 people
- Sponsor
- Celgene Corporation
Multiple Myeloma
Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD
The purpose of this study is to test the effectiveness and safety of adding cyclophosphamide or lenalidomide to the VD combination in the treatment of patients with multiple myeloma that have achieved a stable response after 4…
- Trial name
- SEQUENTIAL (NCT00908232)
- Testing
- Cyclophosphamide, Bortezomib, Dexamethasone
- Where
- 42 sites in France, Germany and 8 more
- Volunteers
- 163 people
- Sponsor
- Janssen-Cilag International NV
Relapsed or Refractory Multiple Myeloma
Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
The purpose of this study is to evaluate the clinical activity of vorinostat in combination with bortezomib in participants with relapsed or refractory multiple myeloma after at least 2 prior treatment regimens.
- Trial name
- NCT00773838
- Testing
- Vorinostat, Bortezomib, Dexamethasone
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC